

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 May 2019 (31.05.2019)



(10) International Publication Number
WO 2019/102311 A1

(51) International Patent Classification:

C07D 471/10 (2006.01) A61P 3/10 (2006.01)
C07C 215/10 (2006.01) A61K 31/438 (2006.01)
A61P 1/16 (2006.01)

(21) International Application Number:

PCT/IB2018/058966

(22) International Filing Date:

14 November 2018 (14.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/589,256 21 November 2017 (21.11.2017) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **FERNANDO, Dilinie**; 6 Driftwood Road,
Jamaica Plain, Massachusetts 02130 (US). **LACASSE,
Shawn M.**; 72 Haley Meadow Road, Griswold, Connecticut

06351 (US). **WIGLESWORTH, Kristin**; 20037 Wanegarden Ct., Germantown, Maryland 20874 (US).


(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CRYSTALLINE 2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL SALT OF 4-(4-(1-ISO-PROPYL-7-OXO-1,4,6,7-TETRAHYDROSPIRO[INDAZOLE-5,4'-PIPERIDINE]-1'-CARBONYL)-6-METHOXYPIRIDIN-2-YL)BENZOIC ACID

FIG. 1



(57) Abstract: The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.

[Continued on next page]

WO 2019/102311 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*